<ѻýҕl>Lung Cancer Survival Continues to Rise With Immunotherapyѻýҕl> Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo Apr 29, 2021
<ѻýҕl>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancerѻýҕl> Questions about generalizability of results with China-developed therapies Apr 14, 2021
<ѻýҕl>A Win for Nivolumab as Preoperative Therapy for Lung Cancerѻýҕl> Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<ѻýҕl>USPSTF Expands Lung Cancer Screening Criteriaѻýҕl> Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
<ѻýҕl>Entrectinib Impresses in Certain Lung Cancersѻýҕl> Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
<ѻýҕl>New Targeted Therapies Show Promise in Cancerѻýҕl> Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<ѻýҕl>Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLCѻýҕl> More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
<ѻýҕl>New Drug OK'd for Chemo-Induced Myelosuppression in SCLCѻýҕl> CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
<ѻýҕl>Dustin Diamond's Small Cell Lung Cancerѻýҕl> "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
<ѻýҕl>KRAS Inhibitor Continues to Impress in NSCLCѻýҕl> Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
<ѻýҕl>Nab-Paclitaxel as Possible Option for Relapsed NSCLCѻýҕl> Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
<ѻýҕl>Should COVID-Strained Centers Hit Pause on Lung Cancer Screening?ѻýҕl> A debate on what stopping scans would do to health systems, patients Feb 01, 2021
<ѻýҕl>Promising Data for Preop Checkpoint Inhibition in NSCLCѻýҕl> Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
<ѻýҕl>First-Ever Survival Bump in Relapsed Mesotheliomaѻýҕl> OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
<ѻýҕl>Dual Checkpoint Blockade No Help in PD-L1-High NSCLCѻýҕl> Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
<ѻýҕl>COVID Affects Cancer Care, Patients' Mental Healthѻýҕl> Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
<ѻýҕl>Montana Oncologist Fired for Misdiagnosing, Overtreating Patientsѻýҕl> But some rally around him Jan 26, 2021
<ѻýҕl>Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemoѻýҕl> News, features, and commentary about cancer-related issues Jan 21, 2021
<ѻýҕl>Targeted Combo Fails in EGFR-Mutant NSCLCѻýҕl> Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
<ѻýҕl>Baby Boys Get Cancer From Mom During Birthѻýҕl> Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
<ѻýҕl>Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancerѻýҕl> But unusual adverse events may hold therapy back Nov 18, 2020
<ѻýҕl>CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppressionѻýҕl> Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
<ѻýҕl>Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLCѻýҕl> Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
<ѻýҕl>Drug Active in 'Undruggable' KRAS-Mutant NSCLCѻýҕl> Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
<ѻýҕl>A Closer Look at FDA Decision to Pull Lorcaserinѻýҕl> More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision Sep 09, 2020
<ѻýҕl>Even 'Light' Smoking Ups Lung Cancer Riskѻýҕl> Mortality approaches that of heavy smokers Sep 09, 2020
<ѻýҕl>In Lupus, Older Age and Male Sex Raise Cancer Riskѻýҕl> Role of most medications, though, not yet clear Aug 21, 2020
<ѻýҕl>Chemo-Free Regimen Boosts OS in Mesotheliomaѻýҕl> Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
<ѻýҕl>Another ALK Drug Tops Crizotinib in First-Line NSCLCѻýҕl> Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
<ѻýҕl>COVID-19 More Deadly Than Cancer Itself?ѻýҕl> Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
<ѻýҕl>The Serious Conversation: Delivering Bad News by Telemedicineѻýҕl> As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
<ѻýҕl>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻýҕl> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻýҕl>COVID-19 in Thoracic Cancer Patients a Killerѻýҕl> Most cancer patients hospitalized May 28, 2020
<ѻýҕl>Paradigm Shift Coming for Early NSCLC?ѻýҕl> Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer May 28, 2020
<ѻýҕl>End of Life and COVID-19; DCIS Doubles Cancer Risk; Training for 'Bad News'ѻýҕl> News, features, and commentary about cancer-related issues May 28, 2020
<ѻýҕl>6-Week Keytruda Safe, Effective in Melanomaѻýҕl> Schedule gets FDA approval for all adult indications Apr 30, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>How Prevalent Is Checkpoint Inhibitor Thyroid Dysfunction, Really?ѻýҕl> Real-world data offer word of caution for oncologists Apr 01, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>No DNA Damage Seen With Single Low-Dose CT Scanѻýҕl> Some reassurance for annual lung cancer screening safety Mar 10, 2020